IPIX — Innovation Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.31m
- $0.14m
Annual income statement for Innovation Pharmaceuticals, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.423 | 0 | 0.018 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.45 | 6.91 | 9.02 | 6.77 | 3.11 |
| Operating Profit | -6.45 | -6.49 | -9.02 | -6.75 | -3.11 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.68 | -6.65 | -13.9 | -7.04 | -3.17 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.68 | -6.65 | -13.9 | -7.04 | -3.17 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.68 | -6.65 | -13.9 | -7.04 | -3.17 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.68 | -6.65 | -13.9 | -7.04 | -3.17 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.049 | -0.02 | -0.036 | -0.014 | -0.006 |